With more than one million operations a year, cardiac surgery with cardiopulmonary bypass is one of the most common major surgical procedures worldwide. 1 Patients are admitted to intensive care units (ICUs) after cardiac surgery, where they often spend a period of time mechanically ventilated until deemed ready for extubation, whereupon they then receive oxygen therapy via a range of devices. 2 Postoperative complications increase morbidity and mortality and lead to prolonged ICU and hospital length of stay. 3 A contributing mechanism of postoperative respiratory complications is atelectasis, which may be present in up to 90% of cardiac surgical patients. 4 5 Atelectasis is resistant to simple techniques such as patient positioning and incentive spirometry. 6 Lung recruitment manoeuvres and positive airway pressure may reduce atelectasis formation, but this effect is lost after extubation. 7 Prophylactic nasal continuous positive airway pressure has been shown to reduce respiratory complications after cardiac surgery. 3 Nasal high-flow oxygen therapy (NHF) delivers lowlevel, flow-dependent positive airway pressure, and may be better tolerated than non-invasive ventilation and enhance washout of nasopharyngeal dead space improving oxygenation. 8 -12 There have only been a few randomized controlled trials assessing the clinical utility of NHF in adult patients after cardiac surgery-all in patients who have respiratory failure before commencing the therapy. 13 -15 No study has assessed the prophylactic use of NHF in the postoperative period. The hypothesis that this phase II study set out to test was that the routine administration of NHF would lead to improved oxygenation after cardiac surgery compared with usual care oxygen therapy.
Methods
A pragmatic, open-label randomized controlled trial was undertaken at a single study centre in a large metropolitan hospital. The study was approved by the Regional Ethics Committee (NTX/10/12/131). Written informed consent was obtained from all study participants before enrolment. The study was registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12610000973011) and the protocol has been published previously. 16 
Study participants
All patients undergoing elective cardiac surgery utilizing cardiopulmonary bypass were eligible for inclusion in this study if aged ≥18 yr and undergoing surgery involving full median sternotomy. The exclusion criteria were contraindication to NHF, e.g. presence of a nasal septal defect, and previous recruitment. Patients were consented to the study and baseline observations made before operation. If participants had not met the extubation criteria by 10 a.m. the day after surgery (Day 1), they were not randomized. This approach ensured that participants with a typical postoperative trajectory were randomized.
Randomization
Randomization was by computer-generated random numbers in blocks of 12, with the sequence generated by an independent statistician, stratified by body mass index (BMI) ,35 or BMI ≥35. Allocation concealment was maintained by using opaque, sealed, sequentially numbered envelopes prepared by a person not involved with the study.
Study treatments
Once the participant was deemed clinically 'ready for extubation' (in accordance with unit protocol), allocation was revealed, the participant extubated, and allocated therapy commenced. Patients were cared for in the ICU and then, if condition allowed, transferred to the postoperative ward the day after surgery. Study therapy for both groups continued until 9 a.m. on Day 2. An algorithm guided clinicians when study participants required an escalation of respiratory support (Fig. 1 ) . 
Statistical analysis
Although we assumed that there would be no difference in failure rate in high-BMI vs low-BMI patients, we stratified for BMI at randomization to ensure balance between groups for this possible prognostic factor. A pre-trial audit of patients at the study site found the incidence of patients recording a 
Results

Patients' characteristics
Over 14 months, 416 patients were enrolled into the study of whom 341 were randomized (Fig. 2) . One patient in the NHF arm withdrew consent for use of any data; one withdrew on Day 2 of the study but did allow use of data collected up to that point; and one did not have Day 3 outcome data collected. Therefore, a total of 338 patients were available for analysis of primary outcome. Of the 340 patients enrolled, 169 were allocated to nasal high flow and 171 to usual care. Baseline characteristics of the group are described in Table 1 . Mean bypass time across the whole group was 110 min (SD 53), and 13 patients had surgery performed without cardiopulmonary bypass even though this was scheduled. 
Primary outcome
Secondary outcomes
Measures of oxygenation are shown in Figure 3 . Arterial blood gas measurements did not differ significantly between groups for pH and Pa CO 2 measurements; however, mean (Table 2 ). In 20 patients tolerability of NHF caused early removal-12 complained of excess heat.
The number of patients requiring an escalation of respiratory support therapy was significantly different ( Table 3) . The main reason for escalation in respiratory support was impaired oxygenation. In the usual care group, 6 patients required therapy with a high-flow face mask, 12 required NHF, 5 required non-invasive ventilation (NIV) (CPAP or BiPAP), and 54 required reintroduction of oxygen therapy after discontinuation of study allocation on Day 2. In the NHF group, seven patients required an increase in NHF flow .45 litre min 21 or reintroduction of the therapy after discontinuation of study period, nine required NIV (CPAP or BiPAP), and two required re-intubation and mechanical ventilation. A further 29 required reintroduction of oxygen therapy by means of low-flow nasal cannulae after discontinuation of study allocation on Day 2. On Day 28, there was no difference in patient status. Most patients (98.8%) were alive and discharged from ICU (167 usual care vs 168 NHF), two had died (one usual care and one NHF giving an overall 28-day mortality of 0.6%), and two usual care patients were alive, but still in the study hospital. Twenty-eight patients had seen their general practitioner for respiratory complaints since discharge from hospital, of which 23 had had antibiotics prescribed (12 usual care vs 11 NHF, P¼0.83).
Discussion
The routine use of NHF from extubation to Day 2 after cardiac surgery did not significantly increase Sp O 2 /FI O 2 ratio on Day 3 after surgery. A weak association with a lower Pa CO 2 and a lower requirement for escalation of respiratory support were found.
The prospective nature of the study, group enrolled, use of a randomized controlled trial design, and the hypothesis differ An open-label, phase II study of routine high-flow nasal oxygen therapy from those of most studies so far that have evaluated NHF in a range of patient populations. This study is the first to aim to determine whether the use of NHFcan reduce the development of respiratory complications after cardiac surgery. Three studies have enrolled cardiac surgical patients, but all have enrolled patients after operation once patients were deemed to exhibit signs of respiratory dysfunction or hypoxaemia. 13 -15 Patient baseline characteristics are comparable with those of these studies and we feel that our findings are generalizable to this patient population.
Previous studies have assessed the efficacy of prophylactic NIV post-extubation in cardiac surgery patients. These studies have shown an improvement in gas exchange; reduction in pulmonary complications and work of breathing; and decrease in ICU and hospital length of stay. 3 5 19-22 However, NIV is not without its difficulties. In many hospitals, it can only be used in an ICU/high dependency unit setting and success often depends on tolerability and fit of the interface, which may impede the ability of the patient to eat, drink, and communicate. Improved comfort scores have been reported with NHF compared with NIV, 2 11 12 23 but in our study we found that patients comfort scores were significantly lower in the NHF group compared with usual care. We believe that the difference in comfort scores found in this study may be because the trial participants were a reasonably 'well' group compared with the other studies, which have enrolled patients suffering acute respiratory failure who seem to benefit more from NHF. In our experience, once 'sicker' patients with a higher inspiratory flow demand start to recover, they too start to find NHF less comfortable and request removal of the therapy. Perhaps, this is an indicator of who may require and benefit the most from NHF. Comfort and tolerability of therapy remains an important consideration when choosing an appropriate oxygen delivery device for patients.
Randomized n=341
Randomized to nasal high flow n=170
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Lost to follow-up n=0
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Analysed n=169
Consent withdrawn n=0
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Not extubated by 10 a.m. n=74
Clinician preference for O 2 therapy at extubation n=1
Assessed for eligibility n=725 Excluded n=309
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Declined participation n=144
Exclusion criteria present n=5
Other reason n=22 No significant heterogeneity was found in the primary outcome after subgroup analysis was undertaken for sex, BMI, ejection fraction, and usage of the internal mammary artery for bypass grafting in patients undergoing coronary artery bypass graft (CABG) surgery. Previous work has shown a link between gender and amount of airway pressure generated by NHF, but was observational and used healthy volunteers. 24 The evidence surrounding the effect of BMI on NHF results is mixed with weight and BMI having no influence in healthy adults, 24 but being associated with generated airway pressure in neonates. 25 A recent observational study of cardiac surgical patients experiencing postoperative respiratory dysfunction treated with NHF found that increases in end expiratory lung impedance were influenced by BMI, with larger increases associated with higher BMIs (P,0.001). 14 However, the mean BMI in that study was 32 kg m 22 while the mean BMI in the NHF group of our study was 28.4 kg m 22 . An open-label, phase II study of routine high-flow nasal oxygen therapy A reduction in escalation of therapy is a finding similar to that of a previous study, 13 which also reported that more patients allocated to NHF succeeded on their therapy compared with those allocated to high-flow humidified face mask (HFFM). That study also found a difference in NIV rates between patients allocated to NHF and those allocated to HFFM therapy although the study was not powered to detect such a treatment effect. The exact mechanism by which NHF reduces the need for escalation of therapy remains to be elucidated, although it is hypothesized that the low-level airway pressure provided by the system may play a role in this, improving gas exchange and reducing respiratory effort. 13 In contrast to previous work, 14 23 26 -28 this study found no significant difference in respiratory rate, cardiovascular parameters, and measures of oxygenation between the groups.
Study strengths and limitations
Strengths of this study include the pragmatic design used leading to timely enrolment and completion of the study and generalizability of study results as all patients presenting for cardiac surgery were considered for enrolment as opposed to specific high-risk groups. A protocol was developed that was easily instituted in both the ICU and the postoperative ward to guide clinicians on escalation therapies for participants (Fig. 1) . However, it was not possible to prevent all incidents of cross-over in the usual care group, which would not have truly represented usual care at this institution if NHF had been excluded as an escalation. This approach may have diluted the treatment effect, as more participants had oxygen therapy escalated in the usual group than in the NHF group. However, such an approach is necessary to test routine use of NHF compared with usual care and thus models a real-world of evaluation clinical practices. Finally, this early phase study used a surrogate outcome (Sp O 2 /FI O 2 ratio) as a primary outcome rather than a more patient-oriented outcome, which would have required greater numbers of participants. Surrogate outcomes may be more sensitive to the effect of the therapeutic interventions than patient-oriented outcomes, leading to over-estimation of effects. 29 Such a problem is unlikely to be the case in our trial, with no clear difference in effects.
Conclusion
Routine use of NHF was not associated with an increase in postoperative oxygenation compared with usual oxygen therapy, although it may have been associated with a reduced requirement for escalation of therapy and a slightly lower Pa CO 2 . In the absence of any demonstrable benefit, it would be hard to justify the routine use of NHF after extubation in patients undergoing a normal postoperative trajectory after cardiac surgery.
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